Huma.AI has joined the Microsoft Pegasus Program to enhance its generative AI platform for the life sciences industry. This collaboration with Microsoft will leverage Azure AI to accelerate the development of life-saving medicines and products. Huma.AI’s platform significantly reduces the time required for evidence generation from weeks or months to minutes, allowing customers to focus on developing medical treatments. The company combines advanced natural language processing, large language models, and expert oversight to handle both private and public data with high accuracy and transparency.
Integrated evidence generation is crucial in the life sciences industry because it provides the foundational data from multiple data sources that can enhance research and development, streamline regulatory compliance, optimize marketing strategies, and improve clinical and health policy decisions. Unfortunately, the industry relies on manual curation of such data by subject matter experts, which is time-consuming and error prone, leaving many mission-critical questions unanswered.
Huma.AI, an evidence-generation platform for healthcare and life sciences powered by generative AI, announced a collaboration with Microsoft through its Microsoft for Startups Pegasus program. Joining the program will allow Huma.AI’s proprietary generative AI platform and Microsoft Azure AI to transform life sciences on a global scale, accelerating the development of life-saving medicines and products.
“Our platform accelerates the evidence-generation process from weeks/months to minutes. The time savings allows our customers to focus on their jobs of developing medical treatments to improve people’s lives,” says Dr. Lana Feng, CEO and Co-Founder of Huma.AI. “Joining the Microsoft for Startups Pegasus Program is a significant acknowledgment of our innovative approach to healthcare and life sciences data. We are excited to accelerate our impact on the industry with the support of Microsoft.”
Huma.AI leverages recent advancements in AI and generative AI to create a platform that not only ingests vast amounts of both private and public data but does so with unmatched accuracy and transparency. The evidence-generation engine combines cutting-edge natural language processing, large language models, and expert human oversight. It is designed to meet the stringent requirements of life science applications, ensuring that data handling is both secure and compliant with industry standards.
Greg Kostello, CTO and co-founder of Huma.AI adds, “Microsoft has a strong commitment to innovation in healthcare and life sciences. Their support will enhance our scalability and enable us to meet the complex demands of our enterprise clients more effectively.”
“We support Huma.AI‘s mission to bring life science-grade generative AI to pharma and medical device companies,” said Sally Ann Frank, Worldwide Lead for Health and Life Sciences at Microsoft for Startups. “Their capabilities address the sector’s unique challenges, such as streamlined evidence generation from sensitive and complex data streams and are proving to be helpful for medical affairs and commercial teams to understand health economics and outcomes research (HEOR) and market access.”
Source: PRWeb
